title: [Tuberculosis and HIV co-infection: a therapeutic challenge].
abstract: Tuberculosis (TB) is the most frequent opportunistic infection in patients infected by the Human immunodeficiency virus (HIV). The mortality related to this co-infection can be reduced by the early introduction of an antiretroviral treatment. However, when treating subjects with TB and HIV, interactions between antiretroviral and tuberculostatic treatments can be problematic; also, these patients may develop, under treatment, an immune reconstitution inflammatory syndrome (IRIS). This review aims to summarize the necessary therapeutic adjustments which should be performed when treating patients co-infected with TB and HIV, the most important interactions between HIV and TB treatments, and the medical management of the IRIS.
authors.affiliation: Service de pneumologie, Département des spécialités de médecine, HUG, 1211 Genève 14. florian.charbonnier@hcuge.ch
authors.forename: Florian
authors.initials: F
authors.lastname: Charbonnier
authors.forename: Alexandra
authors.initials: A
authors.lastname: Calmy
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Janssens
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D002755:Choice Behavior; D060085:Coinfection / Q000188:drug therapy*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced; D008954:Models, Biological; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents